Patients were randomized to receive vismodegib ( 150 mg/day orally ) or placebo , in combination with FOLFOX or FOLFIRI chemotherapy plus bevacizumab ( 5 mg/kg ) every 2 weeks until disease progression or intolerable toxicity .
